Cecilia Low Wang (pronounced “lowwong”), MD is an endocrinologist and Professor of Medicine at University of Colorado, Clinician-Scientist at CPC Clinical Research, and a Fellow of the American College of Physicians and the American Association of Clinical Endocrinology. She earned her medical degree at the University of Rochester and did her residency and chief residency in Internal Medicine at the University of Utah. She completed her fellowship in Endocrinology, Metabolism, and Diabetes at the University of Colorado (CU). Dr. Low Wang is Chairperson of the FDA Endocrinologic and Metabolic Drugs Advisory Committee. She is the principal investigator for continuous glucose monitoring trials in the inpatient setting, and remote continuous monitoring to facilitate a dietary intervention in rural Colorado. She is a member of the Academy of Medical Educators and founding Program Director for the primary care Diabetes Fellowship Program at CU. Dr. Low Wang also directs the Glucose Management Team at the University of Colorado Hospital. She has served on a number of committees for the Endocrine Society and currently chairs the Nominating Committee. She is past chair of the American Association of Clinical Endocrinology Disease State Network in Diabetes and was on the Task Force for the 2023 Update of the AACE Consensus Statement Comprehensive Type 2 Diabetes Management Algorithm. She serves on the Lifestyle Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health for the American Heart Association. She co-founded and is on the Executive Board of the American College of Diabetology which developed the first board certification exam for Diabetology, to be held December 2023. She is passionate about medical education and diabetes care, and does bedside teaching, as well as workshops and lectures locally, regionally, and nationally to clinicians and trainees at all levels.